VXRT – Vaxart, Inc.
Float Short %
9.33
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.02
EPS Last/This Y
0.04
EPS This/Next Y
-0.05
Price
0.37
Target Price
4.67
Analyst Recom
Performance Q
-15.61
Relative Volume
Beta
1.14
Ticker: VXRT
18 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-17 | VXRT | 0.3975 | N/A | N/A | 0 |
| 2025-11-18 | VXRT | 0.3983 | N/A | N/A | 0 |
| 2025-11-19 | VXRT | 0.38 | N/A | N/A | 0 |
| 2025-11-20 | VXRT | 0.3662 | N/A | N/A | 0 |
| 2025-11-21 | VXRT | 0.3591 | N/A | N/A | 0 |
| 2025-11-24 | VXRT | 0.3616 | N/A | N/A | 0 |
| 2025-11-25 | VXRT | 0.3573 | N/A | N/A | 0 |
| 2025-11-26 | VXRT | 0.36 | N/A | N/A | 0 |
| 2025-12-01 | VXRT | 0.3795 | 0.07 | 0.00 | 2168 |
| 2025-12-02 | VXRT | 0.3788 | 0.07 | 0.00 | 2168 |
| 2025-12-03 | VXRT | 0.3613 | 0.07 | 0.00 | 2168 |
| 2025-12-04 | VXRT | 0.362 | 0.07 | 0.00 | 2168 |
| 2025-12-05 | VXRT | 0.3664 | 0.07 | 0.00 | 2168 |
| 2025-12-08 | VXRT | 0.366 | 0.07 | 0.00 | 2168 |
| 2025-12-09 | VXRT | 0.3646 | 0.07 | 0.00 | 2168 |
| 2025-12-10 | VXRT | 0.3659 | N/A | N/A | 0 |
| 2025-12-11 | VXRT | 0.362 | N/A | N/A | 0 |
| 2025-12-12 | VXRT | 0.37 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
18 items
«
‹
Current Page1 of 1
›
»
18 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-17 | VXRT | 0.41 | -5.6 | - | -0.29 |
| 2025-11-18 | VXRT | 0.39 | -5.6 | - | -0.29 |
| 2025-11-19 | VXRT | 0.39 | -5.6 | - | -0.29 |
| 2025-11-20 | VXRT | 0.39 | -5.6 | - | -0.29 |
| 2025-11-21 | VXRT | 0.38 | -5.6 | - | -0.29 |
| 2025-11-24 | VXRT | 0.36 | -5.6 | - | -0.29 |
| 2025-11-25 | VXRT | 0.36 | -5.6 | - | -0.29 |
| 2025-11-26 | VXRT | 0.35 | -5.6 | - | -0.29 |
| 2025-12-01 | VXRT | 0.37 | -5.6 | - | -0.29 |
| 2025-12-02 | VXRT | 0.38 | -5.6 | - | -0.29 |
| 2025-12-03 | VXRT | 0.38 | -5.6 | - | -0.29 |
| 2025-12-04 | VXRT | 0.38 | -5.6 | - | -0.29 |
| 2025-12-05 | VXRT | 0.37 | -5.6 | - | -0.29 |
| 2025-12-08 | VXRT | 0.36 | -5.6 | - | -0.29 |
| 2025-12-09 | VXRT | 0.37 | -5.6 | - | -0.29 |
| 2025-12-10 | VXRT | 0.37 | -5.6 | - | -0.29 |
| 2025-12-11 | VXRT | 0.36 | -5.6 | - | -0.29 |
| 2025-12-12 | VXRT | 0.37 | -5.6 | - | -0.29 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
18 items
«
‹
Current Page1 of 1
›
»
No data found
[stock_market_widget type="chart" template="candlestick" assets="VXRT" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.1
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
4.29
Institutional Transactions
Beta
1.14
Average Sales Estimate Current Quarter
2
Average Sales Estimate Next Quarter
2
Fair Value
Quality Score
20
Growth Score
37
Sentiment Score
19
Actual DrawDown %
98.5
Max Drawdown 5-Year %
-98.7
Target Price
4.67
P/E
Forward P/E
PEG
P/S
1.54
P/B
1.6
P/Free Cash Flow
EPS
-0.26
Average EPS Est. Cur. Y
-0.29
EPS Next Y. (Est.)
-0.34
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
-216.4
Return on Equity vs Industry %
-201.4
EPS 1 7Days Diff
EPS 1 30Days Diff
0.05
EBIT Estimation
[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”VXRT” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”VXRT” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Sector: Healthcare
Industry: Biotechnology
Employees: 105
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
stock quote shares VXRT – Vaxart, Inc. Stock Price stock today
news today VXRT – Vaxart, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VXRT – Vaxart, Inc. yahoo finance google finance
stock history VXRT – Vaxart, Inc. invest stock market
stock prices VXRT premarket after hours
ticker VXRT fair value insiders trading